CD274 and neoplasm: Due to a hyperactivated immune system [61], tumor anti-PD-L1/PD-1 immunotherapy can induce pain in cancer patients, including abdominal pain, arthralgia, acute low back pain, headache and so on [62–65, 112, 113].